These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hepatic myeloid-derived suppressor cells in cancer. Medina-Echeverz J; Eggert T; Han M; Greten TF Cancer Immunol Immunother; 2015 Aug; 64(8):931-40. PubMed ID: 26133122 [TBL] [Abstract][Full Text] [Related]
4. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Hu CE; Gan J; Zhang RD; Cheng YR; Huang GJ Scand J Gastroenterol; 2011 Feb; 46(2):156-64. PubMed ID: 20822377 [TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Mizukoshi E; Yamashita T; Arai K; Terashima T; Kitahara M; Nakagawa H; Iida N; Fushimi K; Kaneko S Cancer Immunol Immunother; 2016 Jun; 65(6):715-25. PubMed ID: 27083166 [TBL] [Abstract][Full Text] [Related]
6. The role of cytokines in hepatocellular carcinoma. Budhu A; Wang XW J Leukoc Biol; 2006 Dec; 80(6):1197-213. PubMed ID: 16946019 [TBL] [Abstract][Full Text] [Related]
7. Individualized precision treatment: Targeting TAM in HCC. Li Z; Wu T; Zheng B; Chen L Cancer Lett; 2019 Aug; 458():86-91. PubMed ID: 31129147 [TBL] [Abstract][Full Text] [Related]
8. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929 [TBL] [Abstract][Full Text] [Related]
9. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Marotta F; Vangieri B; Cecere A; Gattoni A Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567 [TBL] [Abstract][Full Text] [Related]
10. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Dahmani R; Just PA; Perret C Clin Res Hepatol Gastroenterol; 2011 Nov; 35(11):709-13. PubMed ID: 21778132 [TBL] [Abstract][Full Text] [Related]
11. Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages? Zhang CH; Xu GL; Jia WD; Ge YS; Wang W Hepatogastroenterology; 2010; 57(97):114-6. PubMed ID: 20422884 [TBL] [Abstract][Full Text] [Related]
12. Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Kondo Y; Shimosegawa T Int J Mol Sci; 2015 Feb; 16(2):3307-22. PubMed ID: 25654227 [TBL] [Abstract][Full Text] [Related]
13. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. Zhao W; Xu Y; Xu J; Wu D; Zhao B; Yin Z; Wang X Int Immunopharmacol; 2015 Jun; 26(2):314-21. PubMed ID: 25891236 [TBL] [Abstract][Full Text] [Related]
14. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. Li W; Xiao J; Zhou X; Xu M; Hu C; Xu X; Lu Y; Liu C; Xue S; Nie L; Zhang H; Li Z; Zhang Y; Ji F; Hui L; Tao W; Wei B; Wang H J Clin Invest; 2015 Nov; 125(11):4239-54. PubMed ID: 26457732 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972 [TBL] [Abstract][Full Text] [Related]
16. JNK1, a potential therapeutic target for hepatocellular carcinoma. Chen F; Beezhold K; Castranova V Biochim Biophys Acta; 2009 Dec; 1796(2):242-51. PubMed ID: 19591900 [TBL] [Abstract][Full Text] [Related]
17. Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. Nishida N; Kudo M Oncology; 2017; 92 Suppl 1():40-49. PubMed ID: 27764823 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Jeng KS; Chang CF; Jeng WJ; Sheen IS; Jeng CJ Crit Rev Oncol Hematol; 2015 Jun; 94(3):337-47. PubMed ID: 25680939 [TBL] [Abstract][Full Text] [Related]
19. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Cariani E; Missale G Liver Int; 2019 Sep; 39(9):1608-1621. PubMed ID: 31314948 [TBL] [Abstract][Full Text] [Related]
20. The yin and yang of evasion and immune activation in HCC. Makarova-Rusher OV; Medina-Echeverz J; Duffy AG; Greten TF J Hepatol; 2015 Jun; 62(6):1420-9. PubMed ID: 25733155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]